Show simple item record

dc.contributor.authorDuPage, Michel J.
dc.contributor.authorJacks, Tyler E.
dc.date.accessioned2016-10-13T19:02:20Z
dc.date.available2016-10-13T19:02:20Z
dc.date.issued2013-04
dc.identifier.issn09527915
dc.identifier.urihttp://hdl.handle.net/1721.1/104801
dc.description.abstractCancer is a complex disease that can originate in virtually all the tissues of the body, and tumors progress through many different stages during their development. While genetic mutations in the emerging cancer cells drive this disease, it has become increasingly clear that cancer development is strongly influenced by the surrounding microenvironment. Cells of the immune system are critical components of this extrinsic network of cancer regulators, contributing significantly to the microenvironment of most cancers and either promoting or inhibiting the initiation and progression of this disease. Genetically engineered mouse (GEM) mouse models of spontaneous cancer are starting to shape our understanding of how antitumor T cells may act to prevent or inhibit cancer progression in some settings and not others. Lessons learned from investigating spontaneous mouse cancer models have important implications for directing clinical efforts that attempt to direct a cancer patient's immune system to eradicate their disease.en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (Grant 1 U54 CA126515-01)en_US
dc.description.sponsorshipNational Cancer Institute (U.S.) (Cancer Center Support (core) Grant P30-CA14051)en_US
dc.description.sponsorshipJohn D. Proctor Foundation (Margaret A. Cunningham Immune Mechanisms in Cancer Research Fellowship Award)en_US
dc.description.sponsorshipHoward Hughes Medical Institute (Investigator)en_US
dc.description.sponsorshipVirginia and Daniel K. Ludwig Graduate Fellowshipen_US
dc.language.isoen_US
dc.publisherElsevieren_US
dc.relation.isversionofhttp://dx.doi.org/10.1016/j.coi.2013.02.005en_US
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs Licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.sourcePMCen_US
dc.titleGenetically engineered mouse models of cancer reveal new insights about the antitumor immune responseen_US
dc.typeArticleen_US
dc.identifier.citationDuPage, Michel, and Tyler Jacks. “Genetically Engineered Mouse Models of Cancer Reveal New Insights About the Antitumor Immune Response.” Current Opinion in Immunology 25, 2 (April 2013): 192–199en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biologyen_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.approverJacks, Tyler E.en_US
dc.contributor.mitauthorDuPage, Michel J.
dc.contributor.mitauthorJacks, Tyler E.
dc.relation.journalCurrent Opinion in Immunologyen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsDuPage, Michel; Jacks, Tyleren_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0001-5785-8911
dspace.mitauthor.errortrue
mit.licensePUBLISHER_CCen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record